All In Biotech

Drug Trial Radar · NCT06239116

A Study of RM-718 in Healthy Subjects and Patients With MC4R Pathway Impairment

A Study of RM-718 Weekly Formulation in Healthy Subjects With Obesity and in Patients With Obesity Due to MC4R Impairment

Last checked: Nov 20, 2026Latest source record: Oct 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingRandomized with 111 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

111

Actual

Start

Mar 5, 2024

Primary completion

May 7, 2027

Study completion Nov 1, 2028

Sponsor

Lead sponsor
Rhythm Pharmaceuticals, Inc.Industry
Sponsor type
Industry
First posted
Feb 2, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 12 years, up to 65 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the safety, tolerability, and PK of RM-718 in healthy subjects with obesity and in patients with MC4R Pathway Impairment

Conditions

  • Hypothalamic Obesity
  • Prader-Willi Syndrome
  • PWS

Interventions

  • Part A: RM-718 or placebo (matched to specific RM-718 dose cohort)Drug

    Single ascending dose of RM-718 or placebo (matched to specific RM-718 Part A dose cohort)

  • Part B: RM-718 or placebo (matched to specific RM-718 dose cohort)Drug

    Multiple ascending doses of RM-718 or placebo (matched to specific RM-718 Part B dose cohorts)

  • Part C: RM-718Drug

    Multiple ascending doses of RM-718

  • Part D: RM-718Drug

    Multiple ascending doses of RM-718

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Parts A, B, C, D: Safety and Tolerability Assessed by Number of Study Participants with Treatment-Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)Time frame: From Day 1 through the Safety-Follow-up call (up to Day 43 for all Part A cohorts, up to Day 70 for all Part B cohorts, up to Day 140 for Part C cohort, up to Day 210 for Part D cohort)

Locations

7 sites in 1 country. Site status is shown where the registry gives one.

  • UAB Pediatric Endocrinology (Part C and Part D)

    Birmingham, Alabama

  • Ann and Robert H. Lurie Children's Hospital of Chicago (Part C and Part D)

    Chicago, Illinois

  • Boston Children's Hospital (Part C only)

    Boston, Massachusetts

  • Brigham and Women's Hospital (Part C and Part D)

    Boston, Massachusetts

  • Vanderbilt University Medical Center (Part C only)

    Nashville, Tennessee

  • Worldwide Clinical Trials (Part A and Part B)

    San Antonio, Texas

  • University of Utah Pediatric Endocrine Clinic (Part C and Part D)

    Salt Lake City, Utah

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.